Vaxcyte
PCVX
38 hedge funds and large institutions have $1.13B invested in Vaxcyte in 2020 Q2 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
74.29% more ownership
Funds ownership: 0% → 74.29% (+74%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$177M |
| 2 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$166M |
| 3 |
Janus Henderson Group
London,
|
+$152M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$151M |
| 5 |
A
Abingworth
London,
United Kingdom
|
+$134M |
Top Sellers
PCVX Hedge Fund Activity: Q2 2020 in Review
38 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2020, worth a combined $1.13B.
Buyers outnumbered sellers: 38 funds opened new PCVX positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $177M.
- 38 institutional investors held Vaxcyte (PCVX) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $1.13B of Vaxcyte stock for Q2 2020.
- 38 funds opened new Vaxcyte positions in Q2 2020 and 0 closed out, a net change of +38 holders.
- The largest Vaxcyte buyer in Q2 2020 was RA Capital Management, an estimated $177M added.
Based on aggregated 13F filings for Q2 2020.